CorMedix (CRMD) Stock News: November 2026
$CRMD · 1 story in November 2026November 2026
newest first · direct subject stories onlyCorMedix Q3 revenue beats consensus, suspends 2027 DefenCath guidance on CMS changes
CorMedix Therapeutics reported Q3 revenue of $54.5M (above $51.2M consensus), net loss of $14.7M, and adjusted EBITDA of $3.1M. The company maintained FY2026 revenue guidance of $325-345M and narrowed adjusted EBITDA guidance to $130-140M. It suspended 2027 DefenCath revenue guidance due to CMS reimbursement changes. The pending Heron Therapeutics acquisition and REZZAYO sNDA review remain key catalysts.
neutral 50 · impact 70